29 October 2023 in Clinics
To measure Quality of Life (QoL) and costs of Heart Failure (HF) outpatients in Brazil as an introduction to the Value-Based Health Care (VBHC) concept. Cross-sectional study, patients with HF, with ejection fraction <50%, were recruited from three hospitals in Brazil. Two QoL (36-Item Short Form Survey [SF-36] and Minnesota Living with Heart Failure Questionnaire [MLHFQ]) and two anxiety/depression questionnaires were applied. SF-36 scores were stratified by domains. Treatment costs were calculated using the Time-Driven Activity-Based Costing (TDABC) method. Results were stratified by NYHA functional class and sex. From October 2018 to January 2021, 198 patients were recruited, and the median MLHFQ (49.5 [IQR 21.0, 69.0]) and SF-36 scores demonstrated poor QoL, worse at higher NYHA classes. A third of patients had moderate/severe depression and anxiety symptoms, and women had higher anxiety scores. Mean costs of outpatient follow-up were US$ 215 ± 238 for NYHA I patients, US$ 296 ± 399 for NYHA II and US$ 667 ± 1012 for NYHA III/IV. Lab/exam costs represented 30% of the costs in NYHA I, and 74% in NYHA III/IV (US$ 63.26 vs. US$ 491.05). Patients with HF in Brazil have poor QoL and high treatment costs; both worsen as the NYHA classification increases. It seems that HF has a greater impact on the mental health of women. Costs increase mostly related to lab/exams. Accurate and crossed information about QoL and costs is essential to drive care and reimbursement strategies based on value.
1 January 2024 in Arquivos Brasileiros de Cardiologia
LCLarissa Maria de Paula Rebouças da Costa
Larissa Maria de Paula Rebouças da Costa
+12
Background: Brazil is a country with different biomes and social disparities. There are limited data available on regional differences and prognosis of heart failure (HF) in the country. Objective: The Rosa dos Ventos study aims to investigate regional differences and the current prognosis of HF outpatients with reduced or mildly reduced ejection fraction in Brazil. Methods: This is a prospective, multicenter, observational cohort study that will include outpatients older than 18 years with HF and an ejection fraction < 50% in 30 public and private centers distributed in all Brazilian regions. A total of 2,500 patients will be enrolled from June 2021 and October 2023, with a 12-month follow-up period. We will collect data on socioeconomic and clinical status, medical prescription and results of cardiology tests. Follow-up phone calls will be made at 6 and 12 months after inclusion to collect information regarding emergency room visits, hospitalization and mortality. Conclusion: The Rosa dos Ventos study will allow a more accurate characterization of chronic HF in Brazil. This initiative will provide relevant information for the development of effective management strategies to mitigate the impact of this condition on patients and the healthcare system.
16 October 2026 in Journal of Breath Research
Early assessment of treatment response in patients with decompensated heart failure (HF) requiring inotropic support remains challenging. Exhaled breath acetone, a noninvasive marker of ketone body metabolism, may reflect dynamic metabolic changes associated with clinical status. We aimed to evaluate short-term temporal changes in exhaled breath acetone levels following inotropic therapy in patients with decompensated HF. This is a prospective, single-center observational study including patients with HF requiring inotropic therapy. Exhaled breath acetone levels were measured in decompensated HF patients requiring inotropic support using a previously described noninvasive device at hospital admission and within 48 h. The analysis was performed by spectrophotometry after reaction with salicylaldehyde. Ninety-seven patients were enrolled. Baseline median exhaled breath acetone concentration at admission was 7.75 (3.90–12.27) µ g l −1 and decreased to 2.15 (1.10–4.19) µ g l −1 after 48 h of inotrope initiation ( p < 0.001 for within-patient comparison). This reduction was accompanied by clinical improvement in signs of HF decompensation and occurred in patients with or without type 2 diabetes, although the magnitude of this reduction was greater in patients without diabetes ( p = 0.001). Elevated exhaled breath acetone levels were observed in patients with decompensated HF and decreased after initiation of inotropic therapy, paralleling clinical improvement. These findings are hypothesis-generating and larger prospective studies may confirm the potential role of exhaled breath acetone in clinical decision-making.
7 October 2026 in Arquivos Brasileiros de Cardiologia
Sumário […] Diretriz Brasileira de Insuficiência Cardíaca – 2026 Sumário […] Diretriz Brasileira de Insuficiência Cardíaca – 2026